EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSDNOG00000001258
Gene Symbol: CACNA1D
2 Cross references
280 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSDNOG00000019713
Gene Symbol: CACNA1E
2 Cross references
295 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSDNOG00000006166
Gene Symbol: CACNA1F
2 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSDNOG00000047894
Gene Symbol: CACNA1G
2 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSDNOG00000018922
Gene Symbol: CACNA1I
2 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSDNOG00000005652
Gene Symbol: CACNA1S
4 Cross references
266 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSDNOG00000016265
Gene Symbol: CNR1
4 Cross references
207 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSDNOG00000011342
Gene Symbol: CNR2
4 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSDNOG00000014903
Gene Symbol: CA1
2 Cross references
288 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSDNOG00000043949
Gene Symbol: CA12
4 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSDNOG00000032060
Gene Symbol: CA13
4 Cross references
291 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSDNOG00000007176
Gene Symbol: CA14
2 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).